TILT Biotherapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $2.28M

  • Investors
  • 10

TILT Biotherapeutics General Information

Description

Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses for the enhancement of tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors, and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors so as to achieve similar results.

Contact Information

Website
www.tiltbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Tukholmankatu 8 B
  • Biomedicum 2B, (2nd floor)
  • 00290 Helsinki
  • Finland
+358 09 00000000

TILT Biotherapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TILT Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Accelerator/Incubator 07-Feb-2023 $2.28M 000.00 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series A) 07-Feb-2023 000.00 000.00 000.00 Completed Clinical Trials - Phase 1
7. Later Stage VC 16-Jun-2020 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
6. Equity Crowdfunding 02-Apr-2020 00.000 0000 000.00 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series A) 04-Jun-2018 Cancelled Clinical Trials - Phase 1
4. Grant 04-Jun-2018 00.000 00.00 Completed Clinical Trials - Phase 1
3. Seed Round 14-Dec-2016 00.000 00.00 Completed Pre-Clinical Trials
2. Seed Round 30-Sep-2015 $3.48M $5.32M 00.000 Completed Pre-Clinical Trials
1. Seed Round 01-Aug-2013 $1.83M $1.83M 00.000 Completed Pre-Clinical Trials
To view TILT Biotherapeutics’s complete valuation and funding history, request access »

TILT Biotherapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 0,000,000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.00 00.00 00 00.00 00.000
Ordinary 00,000 000.00 000.00 00 000.00 0.000
Series A 212,713 $16.94 $16.94 1x $16.94 1.15%
Series A 202,090 $4.83 $4.83 1x $4.83 1.09%
To view TILT Biotherapeutics’s complete cap table history, request access »

TILT Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvi
Drug Discovery
Helsinki, Finland
21 As of 2023
000.00
000000000000 000.00

000000

at nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000000000000
Rochester, MN
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TILT Biotherapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vyriad Venture Capital-Backed Rochester, MN 00 00000 00000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000 000000000000 Formerly VC-backed Waltham, MA 000 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Newark, CA 0 000.00 00000000000 000.00
000000 000000000 Angel-Backed New York, NY 00000 0000000000 00000
You’re viewing 5 of 36 competitors. Get the full list »

TILT Biotherapeutics Patents

  • 36

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

TILT Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2023505925-A Oncolytic viral vectors encoding variant interleukin-2 (vil-2) polypeptides Pending 11-Oct-2019 0000000000
AU-2020361565-A1 An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide Pending 11-Oct-2019 000000000
CA-3157255-A1 An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide Pending 11-Oct-2019 000000000
EP-4041758-A1 An oncolytic virus vector coding for variant interleukin-2 (vil-2) polypeptide Pending 11-Oct-2019 000000000
AU-2020292610-A1 Oncolytic adenovirus and checkpoint inhibitor combination therapy Pending 14-Jun-2019 C12N15/86
To view TILT Biotherapeutics’s complete patent history, request access »

TILT Biotherapeutics Executive Team (6)

Name Title Board Seat Contact Info
Akseli Hemminki MD Co-Founder, Chief Executive Officer & Board Member
Juha Pihlman Chief Financial Officer & Consultant
Aino Kalervo Chief Operating Officer, Chief Business Officer and Head of Business Management
Henrik Roosvall Business Operations Manager
Kari Varkila Ph.D Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

TILT Biotherapeutics Board Members (8)

Name Representing Role Since
Akseli Hemminki MD TILT Biotherapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
Arto Linnervuo Roschier Legal Advisor & Board Member 000 0000
Jyrki Liljeroos Self Deputy member of the board & Senior Business Advisor 000 0000
Pekka Mattila Self Board Member 000 0000
Timo Ahopelto Lifeline Ventures Strategy Adviser & Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

TILT Biotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TILT Biotherapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Innovation Council Fund Venture Capital Minority 000 0000 000000 0
Tesi Fund of Funds Minority 000 0000 000000 0
Inrgrid Chen Angel (individual) Minority 000 0000 000000 0
PowerBank Ventures Venture Capital Minority 000 0000 000000 0
European Commission Government Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial